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Metformin (METF), historical antihyperglycemic drug, is a likely candidate for lifespan extension, treatment and prevention of
sedentariness damages, insulin resistance, and obesity. Skeletal muscle is a highly adaptable tissue, capable of hypertrophy response
to resistance training and of regeneration after damage. Aims of this work were to investigateMETF ability to prevent sedentariness
damage and to enhance skeletalmuscle function. Sedentary 12-week-oldC57BL/6micewere treatedwithMETF (250mg/kg per day,
in drinking water) for 60 days. METF role on skeletal muscle differentiation was studied in vitro using murine C2C12 myoblasts.
Muscular performance evaluation revealed that METF enhanced mice physical performance (Estimated VO2max). Biochemical
analyses of hepatic and muscular tissues indicated that in liver METF increased AMPK and CAMKII signaling. In contrast, METF
inactivated ERKs, the principal kinases involved in hepatic stress. In skeletal muscle, METF activated AKT, key kinase in skeletal
muscle mass maintenance. In in vitro studies, METF did not modify the C2C12 proliferation capacity, while it positively influenced
the differentiation process and myotube maturation. In conclusion, our novel results suggest that METF has a positive action not
only on the promotion of healthy aging but also on the prevention of sedentariness damages.
1. Introduction
Type 2 diabetes mellitus is a metabolic disorder characterized
by chronic hyperglycemia in association with insulin resis-
tance, impaired relative and/or absolute insulin production,
and altered glucagon secretion [1, 2]. At the onset of dia-
betes two main processes are involved in its pathogenesis:
progressive decline in pancreatic islets function and reduced
insulin sensitivity in peripheral tissues [3]. In particular,
insulin resistance (IR) occurs when insulin effect on muscle
and fat tissues glucose uptake is defective and is not capable
of inhibiting endogenous glucose production by the liver
[4]. Because skeletal muscle is responsible for 70%–80% of
total insulin-stimulated glucose uptake, skeletal muscle IR is
a major determinant of type 2 diabetes [5].
Interactions between genetic and environmental factors,
overnutrition, and sedentary behavior promote the progres-
sion and pathogenesis of IR. In particular, the modifica-
tions that occurred in the global food system during the
past 3-4 decades have created an “obesogenic” environment
contributing to the increase of the obesity epidemic and
consequent IR incidence increase. Unhealthy diet and phys-
ical inactivity are considered among leading causes of the
same diseases characterized by IR. Currently, alleviating this
condition is still one of the key strategies to treat [2, 6].
METF, a widely prescribed drug in type 2 diabetes, is
being increasingly considered for treatment and prevention
of sedentariness damages, as well as for the extension of
healthy lifespan [7]. Recent data showed that long-term diet
supplementation with METF extends healthy lifespan in C.
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elegans and in middle-aged male mice [8, 9]. In addition, our
group demonstrated how acute METF treatment may induce
the generation of neohypertrophic myotubes, by using an in
vitromodel of satellite cells (C2C12 cells line) [10].
Regular practice of physical exercise plays a very impor-
tant role in maintaining a good state of health and physical
well-being [11]. In particular, recent publications showed the
active function of exercise in the reduction and counteraction
of the mechanisms underlying muscle atrophy and degener-
ation related to the onset of peripheral IR [12, 13].
In exercising muscle, increased energy metabolism and
ATP production is obtained by an increased glucose utiliza-
tion. One of the most relevant metabolic effects of exercise
is the enhancement of insulin action [14]. Many factors
may contribute to increasing insulin sensitivity induced by
exercise: a reduction in fat mass, an increase in muscle mass,
and the increase of membrane-bond glucose transporters
(GLUT4) in muscle cells [15].
The effects of physical exercisemay have relevant implica-
tions in the prevention and treatment of metabolic diseases.
In fact, by increasing insulin sensitivity, physical activity can
reduce the risk of pathological conditions such as type 2
diabetes and metabolic syndrome [16].
Understanding the complex mechanisms that regulate
insulin response and the onset of peripheral insulin resistance
represents a primary goal in the treatment of diabetes
and obesity complications, particularly by targeting skeletal
muscle. Given the growing prevalence of the disease and the
conditions of relative sarcopenia related to it, new therapeutic
interventions are able not only to reduce the loss of skeletal
muscle mass but also to stimulate muscle regeneration while
preserving the physiology of viable muscle satellite cells
become necessary.
In order to determine if Metformin could relieve the
sedentariness damages, we studiedMETF effects in sedentary
adult young mice, focusing our attention on METF ability
tomaintainmouse physical performance during submaximal
incremental test.
2. Research Design and Methods
2.1. Materials. Mouse C2C12 myoblasts were purchased
from the European Collection of Animal Cell Cultures
(ECACC). Reagents were purchased from Sigma Chemical
Co. (Saint Louis,MO,USA). Primary antibodies against AKT
(C-20), CAMKII (M-176), calnexin (H-70), ERK1 (K-23),
ERK2 (C-14), GAPDH (FL-335), MyoD (C-20) Myogenin
(D-10), MyHC (H-300), Myf5 (c-20), N-cadherin (H-63),
p70S6 (C-18), SOD2 (FL-222), pERK1/2 (E-4-4) pp70S6
(sc-7984), peroxidase-conjugated secondary antibodies for
Western blot analysis, and rhodamine-conjugated antibod-
ies for immunofluorescence analysis were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Primary
antibodies phospho-AKT (Ser473) (D9E) XP and phospho-
AMPK alpha (Thr172) (40H9) were purchased from Cell
SignalingTechnology (Danvers,MA,USA).Antibody against
Phalloidin (Alexa Fluor 488 Phalloidin, molecular probes-
Invitrogen).
2.2. Animal Studies
2.2.1. Animals. Male C57BL/6mice (𝑛 = 10), purchased from
Charles River Laboratories (Boston, MA, USA), were used
for the study at 12 weeks of age. All animals were kept on a
12 h/12 h light/dark cycle with unlimited access to standard
rodent chow food and water. Mice were divided into two
paired groups: one treated with METF and the other not
treated (CONTR). Every week weight and blood glucose
levels were determined. Blood glucosewasmeasured in blood
collected from the tip of the tail with a portable glucose
measuring device (Bayer, Basel, Switzerland).
2.2.2. METF Treatment. METF (Sigma Chemical Co., Saint
Louis, MO, USA) was added to the drinking water at dose
of 250mg/kg body weight per day, for 60 days. Control
mice received water without METF. As reported in literature
[17], our pilot study confirmed that C57BL/6 mice consumed
7mL water per day; METF addition did not influence water
consumption. Water and METF were changed daily and the
dose adjusted to weight gain each week (Figures 1(a) and
1(b)).
2.2.3. Muscular Performance Exercise Test. Muscular perfor-
mance exercise was evaluated by a submaximal incremental
test prior to and upon completion of the study. Briefly, mice
were placed in adapted treadmill (Columbus Instruments)
for 5min at a 0∘ incline, and then treadmill speed was
increased according to the scheme shown in Figure 1(a)
with 1.5-min intervals at a 15∘ incline (Figure 1(a)). Animals
run until exhaustion, which is defined as remaining on the
shocker plate for more than 5 seconds. Food and water were
unavailable to mice during any running sessions [18]. At the
end of experiment, mice were sacrificed and tissues were
harvested, frozen in liquid nitrogen, and stored at −80∘C for
further analyses.
This study was conducted in compliance with approved
institutional animal care of the University of Milan.
2.3. Cell Culture Experimental Procedures. C2C12 cells were
maintained at 37∘C in humidified 5% CO
2
atmosphere
in a growth medium (GM) containing DMEM (Dulbecco
Modified Eagle Medium) supplemented with 20% (v/v) fetal
bovine serum (FBS), 1% penicillin streptomycin, and 1% l-
glutamine up to 70% confluence. Cell differentiation was ini-
tiated by placing 70% confluent cell cultures in differentiation
medium (DM), containing DMEM supplemented with 1%
horse serum (HS), antibiotics, and 1% l-glutamine. In our in
vitro differentiation model, early myotubes appeared 24–48
hours (h) after serum starvation and neomyotubes formation
was completed after 72 h [19]. Proliferating cells, myoblasts
during differentiation process, and neomyotubeswere treated
with 400 𝜇mMETF. In the control cells METF was not added
to medium. Figure 2 explains experimental study design in
each phase of the protocol, with cell confluence percentage,
treatments start time, and duration.
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Figure 1: Continued.
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Figure 1: METF prevention of sedentariness induced damage in adult male mice C57BL/6. (a) Experimental protocol. (b) Weight
and glycemia variation. (c) Muscular performance evaluation reveals that METF treatment ameliorated the muscular performance. (d)
Muscle tissue analysis indicated that METF had a positive action on AKT activation. (e) Western blot liver analysis showed that METF
increased AMPK activation and decreased ERKs activation. (f) Liver morphological studies: METF increased CAMKII signal. Representative
immunoblots of analyzed proteins are shown. Scale bar 200𝜇m. Significance: ∗𝑝 ≤ 0.05.
2.3.1. Growth Curve and Cell Viability Test. To study
METF action on C2C12 myoblast proliferation, we per-
formed growth curve assay as described [20]. Briefly, C2C12
myoblasts were plated in 60mm × 15mm culture dishes at
40% confluence and grown inGMwith orwithoutMETF and
in DM. Medium was changed every 24 h and the experiment
lasted until control cells achieved 70% of confluence (3 days).
Every day, the cellswere trypsinized, stainedwith trypan blue,
and were counted using a hemocytometer and the average
values for each single day were used to plot a growth curve.
Cell viability was calculated by dividing the nonstained viable
cell count by the total cell count. In addition, morphological
changes were examined daily.
2.4. Western Blot Analysis. Protein extracts, performed as
described elsewhere [21], were obtained from mouse tissues
or cell cultures by using the following lysis buffer containing:
50mM Tris/HCl, pH 7.4, 150mM NaCl, 1% Triton X-100,
1mM sodium orthovanadate (Na
3
VO
4
), 1mM EDTA, 1mM
PMSF, 1mg/mL aprotinin, 1mg/mL leupeptin, and 1mg/mL
pepstatin.
Aliquots of 30 𝜇g supernatant proteins, quantified using
Bradford method, were resolved on SDS-PAGE gel and
transferred onto nitrocellulose membrane (Protran, What-
man Schleicher & Schuell). The membranes were incu-
bated with specific primary antibodies and then with
HRP conjugated anti-species-specific secondary antibodies.
To confirm equal protein loading per sample, we used
antibody anti-calnexin or anti-GADPH. Quantitative mea-
surement of immunoreactive bands intensities, visualized
by an enhanced chemiluminescence method (Amersham
Pharmacia Biotech, Piscataway, NJ, USA), was performed
by densitometric analysis using the Scion Image software
(Scion Corporation, Frederick, MD, USA). Data were then
converted into fold-changes (FC) of the controls [21].
2.5. Immunofluorescence Analysis. For tissues analysis, 7𝜇m
frozen cryosections was fixed in Formaldehyde 4% overnight
at 4C. After that, slides were washed in PBS and incubated
for 1 hour at room temperature with 10% horse serum in PBS
with 0.05% Triton X-100 to block nonspecific binding sites,
while C2C12 cells, fixed and permeabilized as described [22],
were blocked with PBS containing 1% bovine serum albu-
min. Slides or cells were then immunostained with specific
antibodies rhodamine-conjugated and nuclei revealed with
DAPI staining. Slides were mounted with Moviol. Cells were
observed using Nikon Eclipse 50I microscopy and images
were captured using Nis-Elements D 4.00 software (Nikon
Instruments Europe BV, Netherlands). Data were displayed
and analyzed using Adobe Photoshop CS4. Live C2C12 cells
were examined and images were acquired by phase contrast
microscopy using the same microscope and digital system
described above.
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2.6. Statistical Analysis. All experiments were performed
three times. Data are presented as the mean ± SD. Statistical
significances were calculated using 𝑡-tests. Results were con-
sidered significant when 𝑝 ≤ 0.05.
3. Results
3.1. METF Prevention of Sedentariness Induced Damages in
In Vivo METF Experiment. Previous data [8, 9] suggested
the capacity of METF to extend lifespan in the nematode C.
elegans and in middle-aged male C57BL/6 mice, improving
healthspan mice.
We aimed to investigate the possible role of METF in
the prevention of sedentariness induced damages. To achieve
this scope, 12-week-old male C57BL/6 mice were chosen,
maintained in a condition of total absence of exercise, and
treated for 60 days with METF, added in water at the dose of
250mg/kg body weight per day (Figure 1(a)).
We did not observe a significant modification in body
weight between mice randomized to receive METF and
those that did not receive METF (Figure 1(b)). A weight
reduction was observed in both groups, comparing the
beginning and the end of the experiment. In contrast,
we did not observe significant effect in glycemia levels
(Figure 1(b)).
METF effect on muscle performance evaluation revealed
that METF treatment increased speed, time, work, and
estimated maximal oxygen consumption (VO2max) of acute
submaximal incremental exercise in the METF group as
compared to their baseline values (Figure 1(c)). Overall,
muscular performance capacity was therefore increased in
the METF group with respect to the pretreatment condition,
despite aging and despite the lack of previous exercise
training performed whatsoever.
We evaluated METF effects on AKT. The AKT/mTOR
pathway, crucial regulator of skeletal muscle mass, is upregu-
lated during hypertrophy and downregulated during muscle
atrophy [23, 24]. In gastrocnemius muscle of METF treated
animals, AKT activation improved compared with controls
(Figure 1(d)). In addition, a trend of an AKT activation was
detected in quadriceps femoris muscle inMETF treated mice
(Figure 1(d)).
Next, we examinedMETF action on liver (Figure 1(e)). As
already described in literature [25], METF increased AMPK
activation in liver. Liver ERKs activation is associated with
oxidative stress and metabolic dysfunctions, main features
of obesity and diabetes [26]. Interestingly, ERKs activation
was significantly decreased in liver of METF treated mice
(Figure 1(e)).
Immunofluorescence analysis (Figure 1(f)) showed how
METF positively modulates Ca2+/calmodulin dependent
protein kinase (CAMKII) protein levels in liver tissue with
respect to controls, suggesting an important role of METF in
cellular calcium homeostasis.
All together, our in vivo data indicated that METF
could ameliorate not only age induced damage but also
sedentariness induced injury.
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Figure 2: Experimental protocol in vitro studies. C2C12 cells in
proliferative phase, in differentiation, and after differentiation were
treated with 400𝜇MMETF.
3.2. METF Positive Role in Proliferation, Differentiation, and
Hypertrophy in Skeletal Muscle Myoblasts. We also tested
METF action on skeletalmuscle proliferation, differentiation,
and hypertrophic process, using a C2C12 cell lines (Figure 2).
C2C12 murine immortalized cell line provides a good in
vitro model for the study of the major steps of myoblasts
proliferation and differentiation [27, 28]. During C2C12myo-
genic phenotype achievement, Myogenic Regulator Factors
(MRFs) are expressed in a defined sequence;MyoD andMyf5
are primarily expressed, while Myogenin expression is only
induced upon muscle differentiation [27, 28].
400𝜇MMETF did not alter C2C12 proliferative potential
and did not induce cytotoxic effects, as shown in Figure 3(a)
and confirmed in phase contrast images in Figure 3(b). We
also measured MyoD protein level. METF led to a significant
rise in MyoD content, similarly to DM, compared with
control (Figure 3(b)).
Immunofluorescence analysis during proliferation phase
revealed that METF increased the protein expression of
two key markers of early differentiation: Myf5 and MyoD,
suggesting an important role in differentiation induction
and promotion of the myoblast commitment to myotube
(Figure 3(d)). To confirm this, Phalloidin assay (Figure 3(e))
showed that the cells lost their characteristic circular shape,
typical of the active proliferation phase, to achieve a new
elongated morphology.
We explored theMETF effects onmyotube formation.We
analyzedMETF action on differentiation (Figure 2), from the
first phase of differentiation induction (24 h), middle phase
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Figure 3: METF action on C2C12 proliferation phase. (a) METF did not modify C2C12 growth rate and did not induce cytotoxic effects.
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Figure 4: METF action on C2C12 differentiation and neoformed myotubes. (a) Representative Western blots for C2C12 cell lysates and
the indicated antibodies. (b) METF enhanced myotube formation rising MyHC, Myogenin, and N-cadherin protein levels, improved
mitochondrial antioxidant proprieties SOD2, activated ERK, and deactivated p70 signaling pathways. (c) Phase contrast images showed
that differentiation efficacy is optimal in our model, since all competent myocytes became multinucleated myotubes. (d) At 48 h from
differentiation induction, immunofluorescence analysis indicated positive role of METF in CAMKII protein. (e) METF action on neoformed
myotubes: METF improved MyHC protein content and activated ERKs. (f) Immunofluorescence studies confirmed Western blot data of
METF action in hypertrophic process. Scale bar 200𝜇m. Significance: ∗𝑝 ≤ 0.05.
(48 h), and to the end of the process (72 h), when all fusion-
competentmyocytes can formmultinucleatedmyotubes [28].
As shown in Figure 4(b), METF treated cells were charac-
terized by a significant rise in principal marker of myotube
maturation,MyosinHeavyChain (MyHC)protein levelswith
respect to control cells. The similar METF positive action
was observed for N-cadherin, a central cytoskeletal protein
involved in cytoskeletal rearrangement, required to the fusion
ofmyoblast in newmyotubes [29]. To corroborate our results,
which indicated the active role of METF in differentiation
progression, we analyzed Myogenin protein levels. METF
enhanced Myogenin protein content and, in particular, its
expression peak at 48 h (Figure 4(b)).
Protein level of Superoxide Dismutase (SOD2), an
enzyme that efficiently converts superoxide to the less reac-
tive hydrogen peroxide, was significantly increased in METF
cells compared to control cells (Figure 4(b)). This result
suggests that METF could counteract the damage caused
by a sedentary lifestyle by strengthening the antioxidants
mitochondrial functions.
Finally, we investigated METF action on the principal
signaling cascades involved in skeletal muscle formation:
ERKs and p70S6 kinase pathways [23]. METF enhanced
differentiation process through ERKs activation, while it
decreased p70S6 kinase pathway (Figure 4(b)).
After 48 h from differentiation induction, immunofluo-
rescence analysis revealed that CAMKII protein expression
was increased in neoformed myotubes treated with METF
(Figure 4(d)).
Based on our previous data on effect of short time METF
stimulation on the hypertrophic process [10], we studied
the effect of long time METF treatment on neoformed
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myotubes (Figure 4(c)). 24 h of METF stimuli significantly
increased MyHC protein levels (Figure 4(e)). As observed
in all differentiation phases, METF effects were mediated by
ERKs signaling pathways activation (Figure 4(e)).
Also in immunofluorescence images, we observed an
important increase inMyHC andN-cadherin protein content
after METF treatment on neoformed myotubes. Further-
more, METF treatment caused important morphological
changes in terms of morphological parameters (myotubes
length and diameter as shown in Figure 4(f)).
4. Discussion
The effects of physical exercise have relevant implications in
the prevention and treatment of damage induced by “obe-
sogenic environment” characterized by a positive balance
between energy intake and energy expenditure. Moreover,
physical activity represents a primary goal in the treatment
of diabetes and obesity complications, in particular in skeletal
muscle system. To corroborate the fundamental role of phys-
ical activity, the World Health Organization has identified
physical inactivity as the fourth-leading risk factor for global
mortality [30].
We investigated the potential effects of in vivo treatment
with METF, currently candidate drug for lifespan extension,
on the prevention of sedentariness induced damages. Specif-
ically, we analyzed the METF capacity to improve mouse
muscle physical performance.
The study of a protocol of exercise training in mice (Fig-
ure 1(c)) indicated that METF could have positive effects on
muscular performance. Our results, obtained from studying a
model of sedentary healthy mice, confirm the positive METF
action on skeletal muscle function previously obtained in
older mice models [8].
Several recent works suggest how this biguanide drug
could be used in the prevention of aging induced damages
[8, 9, 31]. In this perspective, we studied the key molecular
regulators involved in common aging pathways [32]. AKT
signaling is central in the regulation of muscle function
and, in particular, AKT inactivation is associated with mus-
cle damages induced by aging [23, 33]. We observed that
METF increased the activation of AKT in gastrocnemius
and quadriceps femoris muscles (Figure 1(d)), suggesting
a hypothetical novel use of this drug not only in aging-
related conditions, but also in sedentary-related damaged
muscle conditions. Precisely, for the first time, our work
showed how the beneficial effects of METF occur not only
in groups already characterized by pathological conditions
(e.g., obesity, diabetes, and aging-related disorders) but also
in healthy sedentary populations.
An additional positive action was observed in METF
treated mouse liver; METF deactivates ERK and promotes
CAMKII signaling. ERK activation is crucial in favoring the
development of several liver dysfunctions, such as liver fibro-
sis and hepatocellular cancer [34], while CAMKII pathways
activation is fundamental to preserve liver functions [35].
From these data, it is reasonable to conclude that METF
supplementation could be utilized to keep liver healthy.
We demonstrated in healthy humans that constant aerobic
physical exercise is the clue to avoid lipid steatosis [36].
To further clarify METF cellular mechanisms underlying
the effects obtained in the mouse model, we studied METF
action using an in vitro model of myoblasts, C2C12 cell
line [27, 28]. This cell line represents the gold standard
of immortalized cells to study not only myogenesis but
also the hypertrophy process and its use has allowed us to
investigate METF action on cellular pathways involved in
muscle training, characteristic process of healthy subject.
First, we observed that METF did not modify C2C12
proliferation rate and viability (Figure 3(a)), confirming the
possible use of this biguanide drug without side effects on
skeletal muscle [37]. Those results have important implica-
tions since several tumors are associated with sarcopenia and
cachexia [38], which might benefit fromMETF treatment.
METF accelerated myogenic phenotype acquisition and
myotubes formation (Figures 3 and 4). After 24 h of METF
stimuli on neomyotubes, we observed an increment in mor-
phological parameters (Figure 4(f)), similar to our previous
work where on acuteMETF treatment was administered [10].
This effect is mediated by ERK activation (Figure 4(e)). Our
data indicate that METF should not be considered not only a
drug capable of inactivating the cellular mechanisms related
to muscle injury, but also a drug capable of activating cellular
processes related to muscle strengthening and hypertrophy.
We speculate that this METF capacity to enhance myotubes
formation and hypertrophy could represent a possible expla-
nation of data obtained, in vivo, in mice.
Finally, our results obtained during differentiation phases
showed that SOD2 protein content is increased after METF
stimuli (Figure 4(b)). The intracellular enzymes of the SOD
family act as a primary line of defense to cope with the
deleterious effects of ROS, thereby contributing to an over-
all decrease in oxidative damage. Lower SOD activity is
associated with sedentary lifestyle, characterized by insulin
resistance, suggesting that reduced capacities of antioxidant
enzymes lead to increased oxidative stress in diabetes and
obesity [39]. So, we hypothesize that METF could also act
as an antioxidant agent. This potential effect needs further
investigation.
5. Conclusions
In conclusion, our study reports several novel findings
regarding the use of METF in a condition of absence of
physical activity and specifically: (1) it improvesmice physical
aerobic performance; (2) it ameliorates myotubes formation,
regulating the principal molecular mediators of skeletal
muscle hypertrophy and atrophy; (3) it prevents oxidative
stress damage, modulating ERK and SOD signaling.
The relevance of our results resides in a potential use
of METF (or drugs with similar biological proprieties) to
counteract the damages consequent to sedentariness either
directly (acting onmolecular targets involved in stress condi-
tion) or indirectly, by enhancing the known beneficial phys-
ical activity effects. In this framework, additional research
is necessary, also in humans, to test combined therapeutical
10 Journal of Diabetes Research
use of METF, exercise, and diet to prevent damages of
sedentariness.
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